Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. (se deschide o fereastră nouă)

Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.

Sursă‎: J Pediatr Hematol Oncol 2011;33(5):339-43.

Index‎: PubMed 21602718

DOI‎: 10.1097/MPH.0b013e31821b0770

https://www.ncbi.nlm.nih.gov/pubmed/21602718 (se deschide o fereastră nouă)

Gγ-Xmn I polymorphism: a significant determinant of β-thalassemia treatment without blood transfusion. (se deschide o fereastră nouă)

Ansari SH, Shamsi TS, Munzir S, Khan MT, Erum S, Perveen K, Farzana T, Ashraf M, Mehboob T, Moinuddin M.

Sursă‎: J Pediatr Hematol Oncol 2013;35(4):e153-6.

Index‎: PubMed 23389500

DOI‎: 10.1097/MPH.0b013e31827e8662

https://www.ncbi.nlm.nih.gov/pubmed/23389500 (se deschide o fereastră nouă)

Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT). (se deschide o fereastră nouă)

Ansari SH, Shamsi TS, Siddiqui FJ, Irfan M, Perveen K, Farzana T, Panjwani VK, Yousuf A, Mehboob T.

Sursă‎: J Pediatr Hematol Oncol 2007;29(11):743-6.

Index‎: PubMed 17984691

DOI‎: 10.1097/MPH.0b013e318157fd75

https://www.ncbi.nlm.nih.gov/pubmed/17984691 (se deschide o fereastră nouă)

Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. (se deschide o fereastră nouă)

Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de Montalembert M.

Sursă‎: Blood 2003;102(4):1529-30.

Index‎: PubMed 12702505

DOI‎: 10.1182/blood-2003-01-0117

https://www.ncbi.nlm.nih.gov/pubmed/12702505 (se deschide o fereastră nouă)

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. (se deschide o fereastră nouă)

Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M.

Sursă‎: Transfusion 2007;47(10):1830-6.

Index‎: PubMed 17880608

DOI‎: 10.1111/j.1537-2995.2007.01399.x

https://www.ncbi.nlm.nih.gov/pubmed/17880608 (se deschide o fereastră nouă)

Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. (se deschide o fereastră nouă)

Hashemi A, Abrishamkar M, Jenabzade AR, Eslami Z.

Sursă‎: Iran J Blood Cancer 2009;1(4):147-50.

Index‎: IMEMR 107228

https://www.ijbc.ir/browse.php?a_id=4&sid=1&slc_lang=en (se deschide o fereastră nouă)

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. (se deschide o fereastră nouă)

Karimi M, Haghpanah S, Farhadi A, Yavarian M.

Sursă‎: Int J Hematol 2012;95(1):51-6.

Index‎: PubMed 22180324

DOI‎: 10.1007/s12185-011-0985-6

https://www.ncbi.nlm.nih.gov/pubmed/22180324 (se deschide o fereastră nouă)

Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. (se deschide o fereastră nouă)

Perrine SP.

Sursă‎: Pediatr Ann 2008;37(5):339-46.

Index‎: PubMed 18543545

https://www.ncbi.nlm.nih.gov/pubmed/18543545 (se deschide o fereastră nouă)

A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. (se deschide o fereastră nouă)

Yasara N, Wickramarathne N, Mettananda C, Silva I, Hameed N, Attanayaka K, Rodrigo R, Wickramasinghe N, Perera L, Manamperi A, Premawardhena A, Mettananda S

Sursă‎: Sci Rep. 2022;12(1):2752.

Index‎: PubMed 35177777

DOI‎: 10.1038/s41598-022-06774-8

https://pubmed.ncbi.nlm.nih.gov/35177777/ (se deschide o fereastră nouă)

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. (se deschide o fereastră nouă)

Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC.

Sursă‎: Haematologica 2004;89(10):1172-8.

Index‎: PubMed 15477200

https://www.ncbi.nlm.nih.gov/pubmed/15477200 (se deschide o fereastră nouă)

Hydroxyurea therapy in 49 patients with major beta-thalassemia. (se deschide o fereastră nouă)

Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A.

Sursă‎: Arch Iran Med 2009;12(3):295-7.

Index‎: PubMed 19400608

https://www.ncbi.nlm.nih.gov/pubmed/19400608 (se deschide o fereastră nouă)

Use of hydroxyurea and recombinant erythropoietin in management of homozygous ß⁰ thalassemia. (se deschide o fereastră nouă)

Kohli-Kumar M, Marandi H, Keller MA, Guertin K, Hvizdala E.

Sursă‎: J Pediatr Hematol Oncol 2002;24(9):777-8.

Index‎: PubMed 12468925

https://www.ncbi.nlm.nih.gov/pubmed/12468925 (se deschide o fereastră nouă)

Termination of transfusion dependence in beta-thalassemia: two-year experience with recombinant human erythropoietin. (se deschide o fereastră nouă)

Nişli G, Kavakli K, Aydinok Y, Oztop S, Cetingül N.

Sursă‎: Pediatr Hematol Oncol 1997;14(3):285-7.

Index‎: PubMed 9185215

https://www.ncbi.nlm.nih.gov/pubmed/9185215 (se deschide o fereastră nouă)

Fetal globin gene inducers: novel agents and new potential. (se deschide o fereastră nouă)

Perrine SP, Castaneda SA, Chui DH, Faller DV, Berenson RJ, Siritanaratku N, Fucharoen S.

Sursă‎: Ann N Y Acad Sci 2010;1202:158-64.

Index‎: PubMed 20712788

DOI‎: 10.1111/j.1749-6632.2010.05593.x

https://www.ncbi.nlm.nih.gov/pubmed/20712788 (se deschide o fereastră nouă)